On December 6, 2005, Baum & Company, PA resigned as the principal registered independent public accounting firm of FermaVir Pharmaceuticals, Inc. (the “Company”). From the date of their appointment, to December 6, 2005, the date of their resignation, (i) the reports of Baum & Company, PA on the Company’s financial statements as of and for the years ended April 30, 2005 and 2004 and for the period commencing November 15, 2002 (date of inception) to April 30, 2005 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles and (ii) there were no disagreements with Baum & Company, PA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Baum & Company, PA would have caused them to make reference thereto in their reports on the financial statements for such years.
The Company provided Baum & Company, PA with a copy of this Current Report on Form 8-K on December 7, 2005, prior to its filing with the SEC, and requested that they furnish the Company with a letter addressed to the SEC stating whether they agree with the statements made in this Current Report on Form 8-K, and if not, stating the aspects with which they do not agree. A copy of the letter provided by Baum & Company, PA, dated December 7, 2005, is attached to this Form 8-K as Exhibit 16.1.
On December 6, 2005, the Company engaged JH Cohn LLP (“JHC”) as its principal independent registered public accounting firm. The Company’s audit committee has approved the appointment of JHC as the Company's new principal independent registered public accounting firm.
Prior to engaging JHC the Company did not consult with them regarding either:
1. the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered in the Company's financial statements, and neither a written report was provided to the Company nor oral advice was provided that JHC concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or
2. any matter that was either subject of disagreement or event, as defined in Item 304(a)(1)(iv)(A) of Regulation S-B and the related instruction to Item 304 of Regulation S-B, or a reportable event, as that term is explained in Item 304(a)(1)(iv)(A) of Regulation S-B.
